Dee Pei

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 2.8K citations · Full text

Metabolic Syndrome, Diabetes Management, Cardiovascular Disease +9

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 600 citations · Full text

Metabolic Syndrome, Diabetes Management, Urology +10

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Hiddo J.L. Heerspink, Hans‐Henrik Parving, Dennis L. Andress et al. · The Lancet · 2019 · 589 citations · Full text

Urology, Renal Disease, Renal Events +7

Uric Acid Levels Can Predict Metabolic Syndrome and Hypertension in Adolescents: A 10-Year Longitudinal Study

Hai‐Lun Sun, Dee Pei, Ko‐Huang Lue et al. · PLoS ONE · 2015 · 97 citations · Full text

Obesity, Metabolic Syndrome, Hypertension +13

Bisphosphonate pretreatment attenuates hungry bone syndrome postoperatively in subjects with primary hyperparathyroidism

I‐Te Lee, Wayne Huey‐Herng Sheu, Shih‐Te Tu et al. · Journal of Bone and Mineral Metabolism · 2006 · 73 citations

Bone Disease, Parathyroid Hormone, Parathyroid Disease +7